Research - Sydney, New South Wales, Australia
FivepHusion is an Australian biotechnology company commercialising Deflexifol™ , a novel cancer drug formulation as the replacement and enhancement of standard of care 5-fluorouracil (5-FU) and leucovorin for the treatment of solid tumors. Deflexifol™ demonstrates greater safety and tolerability, leading to higher maximum tolerated dose and enhanced efficacy, including in patients previously resistant to 5-FU treatment. Having treated >50 end stage solid tumor patients, FivepHusion is now preparing to initiate:- a phase 1b trial in a rare paediatric oncology indication,- a phase III registration trial in first line metastatic colorectal cancer.FivepHusion is pursuing global registration and commercialisation of Deflexifol™ as the new standard of care for solid tumor treatment.
Apache
WordPress.org
Google Font API
Google Maps